Tumor News and Research

RSS

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Analyzing the immune microenvironment around Hodgkin lymphoma tumors

The most detailed study of Hodgkin lymphoma, a type of blood cancer, has offered considerable insight into what tumor cells must do to sustain. The Wellcome Sanger Institute discovered that cancer cells utilize signals to attract specific types of immune cells and direct them not to attack.

15 Feb 2023

Versatile molecular toolbox expands the scope of gene regulation

Rice University scientists have enlisted widely used cancer therapy systems to control gene expression in mammalian cells, a feat of synthetic biology that could change how diseases are treated.

15 Feb 2023

Study charts seasonal and circadian genetic variation across the human body

The daily rotation of Earth and its yearly voyage around the Sun marks the natural rhythm of life on the planet.

14 Feb 2023

UChicago scientists shed light on the longstanding puzzle of RNA methylation

University of Chicago scientists have discovered a new wrinkle in our understanding of how our genes work.

14 Feb 2023

Study reveals the mechanisms that prevent effective cancer cell death

Cancer is a disease driven by gene mutations. These mutated genes in cancer fall into two major categories: tumor suppressors and oncogenes. Mutations in tumor suppressor genes can allow tumors to grow unchecked – a case of no brakes – while mutations in oncogenes can activate cell proliferation, pushing the gas pedal all the way to the floor.

14 Feb 2023

Review highlights the pathological significance of CEACAM1, 5, and 6

A new review was published in Genes & Cancer on February 1, 2023, entitled, "CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens."

14 Feb 2023

Two-step screening of aroma compounds reveals a novel and effective modulator of dendritic cells

Dendritic cells (DCs) are important players of the immune system with important functions such as the identification of infectious pathogens, production of cytokines (chemical signalers of the immune system), presentation of antigens to activate T-cells, and more.

13 Feb 2023

A treatment strategy to hasten cancer cell death

Gene mutations are the cause of cancer. Tumor suppressors and oncogenes are the two main groups of these altered genes in cancer. Mutations in oncogenes can drive cell proliferation, pushing the gas pedal to the floor, whereas mutations in tumor suppressor genes can cause tumors to grow unchecked—a situation in which there is no control.

13 Feb 2023

Researchers address new quantitative approaches to better define cancer epigenetic landscape

It is now widely understood that cancer is a disease of acquired defects in genes and gene function.

10 Feb 2023

Protein-rich droplets in cells linked to many unresolved diseases

Most proteins localize to distinct protein-rich droplets in cells, also known as "cellular condensates". Such proteins contain sequence features that function as address labels, telling the protein which condensate to move into.

9 Feb 2023

Complete Genomics Drops Genome Sequencing Price to Sub $100 at AGBT General Meeting

Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. (“MGI”), today launched new revolutionary products and prices at Advances in Genome Biology and Technology (AGBT) General Meeting.

From Complete Genomics 9 Feb 2023

Strata Oncology publishes study validating integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company's proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).

8 Feb 2023